HC Wainwright Has Bearish Outlook for CMPX FY2027 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Stock analysts at HC Wainwright lowered their FY2027 EPS estimates for Compass Therapeutics in a research report issued on Monday, April 28th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.44) per share for the year, down from their previous estimate of ($0.02). HC Wainwright currently has a "Buy" rating and a $24.00 price objective on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics' FY2028 earnings at ($0.13) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

CMPX has been the topic of several other research reports. D. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Monday. Guggenheim reissued a "buy" rating on shares of Compass Therapeutics in a report on Tuesday, April 22nd. Wedbush reissued an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Stock Performance

Shares of CMPX stock opened at $1.86 on Thursday. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The firm has a market capitalization of $257.21 million, a price-to-earnings ratio of -5.03 and a beta of 1.40. The stock's 50-day simple moving average is $2.15 and its 200-day simple moving average is $2.10.

Institutional Trading of Compass Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CMPX. Enavate Sciences GP LLC purchased a new stake in Compass Therapeutics during the 4th quarter worth approximately $11,293,000. Tang Capital Management LLC boosted its stake in shares of Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC increased its position in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after purchasing an additional 2,926,002 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Compass Therapeutics by 138.2% during the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock worth $1,787,000 after purchasing an additional 545,767 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Compass Therapeutics by 512.5% in the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock valued at $395,000 after purchasing an additional 227,864 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

Insiders Place Their Bets

In related news, Director Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Anderman acquired 20,000 shares of the firm's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.